Abstract: The invention relates to pharmaceutical compositions comprising calcium lactate as an active agent and a polysaccharide, polymer, lipid, or a combination thereof. The pharmaceutical compositions are useful treating cancer. The invention also relates to foods and nutrient compositions comprising calcium lactate.

Abstract: A free-flowing solid pharmaceutical formulation comprising one or more active ingredients and a blend comprising sorbitol and liquid paraffin, a package containing the formulation, a process for the manufacture of the formulation and the use of the blend in the formulation.

Abstract: The present invention relates to immediate release formulations of (R)-2-amino-3-phenylpropyl carbamate and methods of using the same to treat disorders.

Abstract: The invention discloses a composition exhibiting enhanced bioavailability comprising tri-molecular complex of a natural compound or a natural compound containing component, a divalent or tri-valent metal ion and a phospholipid embedded in natural matrix. The composition of the invention further exhibits a sustained release profile for the natural compound or natural compound containing component. The invention further discloses a process for manufacturing the tri-molecular complex containing composition.

Abstract: The present invention relates to immediate release formulations of (R)-2-amino-3-phenylpropyl carbamate and methods of using the same to treat disorders.

Abstract: Oral pharmaceutical compositions of sodium oxybate having improved pharmacokinetic properties when administered less than two hours after eating are provided, and therapeutic uses thereof.

Abstract: An orally deliverable dosage system comprises (a) iron in a form of one or more physiologically acceptable iron grades, compounds and/or complexes; and (b) an agent to mitigate one or more gastrointestinal adverse effects of unabsorbed iron, said agent comprising one or both of a zinc component and a chelator component, said zinc component if present comprising one or more physiologically acceptable zinc compounds and/or complexes, and said chelator component if present comprising an ion-chelating compound formulated for release distal to the primary site of iron absorption in the duodenum.

Abstract: Melatonin tablets with a high concentration of citric acid are packaged in a blister package that enhances storage stability. Such a packaging material includes a blister film forming a cavity holding the tablet therein. The blister film includes a polyvinyl chloride (PVC) film having a thickness of 180 ?m to 270 ?m coated with a polyvinylidene chloride (PVDC) coating having a coating weight of 110 g/m2 to 130 g/m2. An aluminum foil lid closes the cavity and encapsulates the tablet within the blister film and lid. The lid has a thickness of 20 ?m to 30 ?m.

Abstract: The present invention relates to a novel directly compressible matrix for the production of tablets which disintegrate rapidly in the presence of moisture, in particular in the mouth.

Abstract: A solid cosmetic composition contains cationic surfactant, a polyhydric C2-C6 alcohol, C8-C30 alcohol or C8-C30 carboxylic acid or salt and a starch fraction, a modified starch or a starch derivative and is used for hair care.

Abstract: An absorption enhancer for polyphenol containing at least one kind of extract selected from the group consisting of an extract from Kochia scoparia (L.) Schrad., an extract from Acacia concinna, an extract from Sanicula europaea, an extract from Bupleurum rotundifolium, and a seed extract from Camellia sinensis, as an active ingredient.

Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.

Abstract: The present invention relates to compositions and methods of treating lysosomal storage diseases and methods of using trehalose.

Abstract: The present invention relates to immediate release formulations of (R)-2-amino-3-phenylpropyl carbamate and methods of using the same to treat disorders.

Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.

Abstract: Certain embodiments of the invention include medical materials and methods comprising a biodegradable hydrophilic hydrogel comprising dispersed lipophilic particles that comprise a therapeutic agent, wherein the lipophilic particles have a low water solubility in physiological saline at physiological temperature.

Abstract: The present invention relates to immediate release formulations of (R)-2-amino-3-phenylpropyl carbamate and methods of using the same to treat disorders.

Abstract: A tampon comprising an absorbent pledget and a time-lapse indicator associated therewith is provided. The time-lapse indicator includes a sensory material surrounded by, embedded in, covered by, or coated with a release-retarding material that protects the sensory material and prevents its release, until after a predetermined period of time has elapsed. The time-lapse indicator is located on or in the tampon or tampon removal string, or, optionally, the tampon packaging. After the time-lapse indicator is activated and a predetermined period of time has elapsed, the sensory material is released and alerts the user that it is time to change the tampon.

Abstract: The present invention provides a solid immediate release dosage form adapted for oral administration of GHB. The solid immediate release dosage form includes an immediate release formulation comprising a relatively high weight-percentage of GHB with a bioavailability similar to that of a liquid GHB dosage form.

Abstract: The present disclosure provides colorant compounds and methods of isolation of the colorant compounds derived from a reaction of genipin and an amine. The colorant compositions comprise purified compounds (e.g., a purified polymer or a purified dimer) obtained from multiple fractioning by chromatography of the reaction resulting material. The purified polymer or dimer can be used as a colorant by itself or in combination with another colorant for imparting color to a food, a drug, a cosmetic, a medical device, and textile products.

Abstract: A fiber includes one or more layers of polymer surrounding a central lumen, and living animal cells disposed within the lumen and/or within at least one of the one or more layers, wherein the fiber has an outer diameter of between 5 and 8000 microns and wherein each individual layer of polymer has a thickness of between 0.1 and 250 microns. Also disclosed are model tissues including such fibers, and method of making such fibers. The fibers can serve as synthetic blood vessels, ducts, or nerves.

Abstract: Embodiments relate to Rifaximin polymorphic, salt, and hydrate forms, methods of producing polymorphic forms and to their use in medicinal preparations and to therapeutic methods using them.

Abstract: An object of the present invention is to provide a gel containing pyrroloquinoline quinone that is capable of easily forming a gel near room temperature and is useful even in the food sector, and a method for producing the gel. According to the present invention, there is provided a gel containing pyrroloquinoline quinone that uses pyrroloquinoline quinone itself as a gelling agent and a method for producing the gel by adding a salt of pyrroloquinoline quinone to water and subsequently adjusting the temperature or the pH to reduce solubility.

Abstract: Disclosed are methods and compositions related to the use of boswellic acids (such as acetyl-11-keto-?-boswellic acid, 11-keto-?-boswellic acid, ?-boswellic acid, acetyl-?-boswellic acid, 9,11-dehydro-?-boswellic acid, acetyl-9,11-dehydro-?-boswellic acid, ?-boswellic acid, acetyl-?-boswellic acid, 11-dehydro-?-boswellic acid, acetyl-9,11-dehydro-?-boswellic acid, lupeolic acid, acetyl lupeolic acid, 12-ursene-2-diketone, incensole, incensole acetate, a derivative, in particular an ester thereof, a pharmaceutically acceptable salt thereof, a combination thereof, or a preparation containing one or more of these compounds) for the human medical or veterinary prophylaxis and/or treatment of: a) damage to and/or inflammation of the islets of Langerhans and/or b) damage to the B-cells of the islets of Langerhans.

Abstract: The invention relates to a solid formulation for the oral administration of olanzapine that comprises a core of anhydrous olanzapine Form I or a pharmaceutically acceptable salt thereof and, optionally, pharmaceutically acceptable excipients, said core being coated with a functional polymer that acts as filmogenic agent. The method for obtaining it comprises: i) providing anhydrous olanzapine Form I or a salt thereof and, optionally, pharmaceutically acceptable excipients in solid form; ii) providing a functional polymer that acts as filmogenic agent; iii) preparing a dispersion of said functional polymer in an aqueous medium,—and applying the dispersion obtained in step iii) onto the solid form of step i).

Abstract: The present invention relates to an enteric tablet with improved bioavailability, which is rapidly disintegrated after reaching the intestine to allow dissolution of the active ingredient, and which characteristically reduces the amount of talc to be used and is free of an alkali component.

Abstract: The present invention comprises methods and compositions for the reduction of oxalate in humans. For example, the invention provides methods and compositions for the delivery of one or more oxalate-reducing enzymes embedded in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions including, but not limited to, hyperoxaluria, absorptive hyperoxaluria, enteric hyperoxaluria, primary hyperoxaluria, idiopathic calcium oxalate kidney stone disease (urolithiasis), vulvodynia, oxalosis associated with end-stage renal disease, cardiac conductance disorders, inflammatory bowel disease, Crohn's disease, ulcerative colitis, and patients who have undergone gastrointestinal surgery and bariatric surgery (surgery for obesity), and/or who have undergone antibiotic treatment.

Abstract: The present invention provides a dry-coated tablet comprising: an inner core containing, as active ingredients, (a) tegafur, (b) gimeracil, and (c) oteracil potassium; and an outer shell.

Abstract: The invention relates to a product for oral administration intended for a pet, comprising extracts of punica granatum (pomegranate). The invention is characterised in that the invention further comprises at least two additional antioxidant compounds chosen from:— soya isoflavone extracts;— L-carnitine; and— taurine.

Abstract: Composition for use in treating bacterial infections, comprising a concentrate or an extract of origanum in combination with at least one concentrate or extract of another plant.

Abstract: A method is provided for producing a sugar-coated preparation including a solid composition containing a pharmacologically active ingredient and a sugar coating layer. The method comprises a step of forming the sugar coating layer with a sugar coating composition containing one or more sugar-alcohols selected from the group consisting of mannitol and erythritol and a polyvinyl alcohol-based resin. The sugar-coated preparation includes a solid composition containing a pharmacologically active ingredient and a sugar coating layer, wherein the sugar coating layer is made of a sugar coating composition containing one or more sugar-alcohols selected from the group consisting of mannitol and erythritol and a polyvinyl alcohol-based resin.

Abstract: The present invention relates to an enteric coating formulation, as well as methods for preparing and using said enteric coating formulation. In particular, the invention relates to an enteric coating formulation that is made up of foodeous approved materials.

Abstract: A novel method for the preparation of a tablet comprising a calcium-containing compound, the method involves a melt granulation process by which a sugar alcohol is melted and embeds the calcium-containing compound so that a sufficient taste masking of the chalkiness is substantially achieved and an unpleasant mouth feel of the calcium-containing compound is substantially avoided, while at the same time obtaining a low tablet volume. The method of the invention is especially suitable for the manufacturing of tablets having a high load of a calcium-containing compound.

Abstract: The present invention relates to collagen hydrolysate and the use thereof for treating and/or preventing cellulite.

Abstract: The present invention relates to a granulate and a pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof and stabilizer, in particular to a pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof and sucrose, polyethylene glycol, cyclodextrin, and combinations thereof and to a process for its preparation. The granulate and the pharmaceutical composition are particularly useful as a medicament, especially for the treatment of urinary incontinence. The present invention relates to use of sucrose, polyethylene glycol, cyclodextrin, and combinations thereof for stabilizing fesoterodine or a salt or a solvate thereof in a pharmaceutical composition.

Abstract: The present invention relates to an improved gelatinous coated dosage form having two end regions coated with gelatinous materials and an exposed circumferential band. Openings are provided in at least the exposed band to reveal the core material. The invention also relates to methods for manufacturing such gelatinous coated dosage forms.

Abstract: A process for producing anionic, nonionic, amphoteric or cationic derivatized polysaccharide products which demonstrate high clarity in surfactant-based compositions. The polysaccharide polymer is reacted for a sufficient time and at a sufficient temperature in the presence of water, caustic, and at least one surfactant. The polysaccharide polymer may optionally be reacted with an oxidizing agent, hydrolytic or proteolytic enzymes, molecular weight reducing agents and a cationizing agent and nonionic agent. The formed derivatized polysaccharide has a lower clarity in water than in an aqueous surfactant system. The derivatized polysaccharide product can be used in personal care and or household care products.

Abstract: The present invention provides a solid immediate release dosage form adapted for oral administration of GHB. The solid immediate release dosage form includes an immediate release formulation comprising a relatively high weight-percentage of GHB with a bioavailability similar to that of a liquid GHB dosage form.

Abstract: The present invention provides a pharmaceutical composition, presented as a solid unit dosage form adapted for oral administration of sodium oxybate. The preferred unit dosage form is a tablet comprising a relatively high weight-percentage of sodium oxybate, in combination with a relatively small weight-percentage of total excipients. This permits the tablets to contain/deliver a pharmaceutically effective amount, e.g., about 0.5-1.5 g of sodium oxybate in each tablet with a delivery profile similar to that of the liquid form. The tablets are bioequivalent to the liquid form.

Abstract: A white coloring composition comprising calcium carbonate as a white pigment. It may be used in the manufacture of food and pharmaceutical products.

Abstract: Composition (C) for coating ingestible solid forms, comprising, per 100% of its mass—from 10% to 90% of a graft copolymer of polyvinyl alcohol and of polyethers (Pi), and—from 10% to 90% by mass of an auxiliary coating agent, characterized in that a non-zero mass proportion of said auxiliary agent is polydextrose. Processes for the preparation and use thereof.

Abstract: Controlled release, discrete, solid particles which contain an encapsulated and/or embedded component such as a heat sensitive or readily oxidizable pharmaceutically, biologically, or nutritionally active component are continuously produced without substantial destruction of the matrix material or encapsulant. A release-rate controlling component is incorporated into the matrix to control the rate of release of the encapsulant from the particles. The additional component may be a hydrophobic component or a high water binding capacity component for extending the release time. The plasticizable matrix material, such as starch, is admixed with at least one plasticizer, such as water, and at least one release-rate controlling component under low shear mixing conditions to plasticize the plasticizable material without substantially destroying the at least one plasticizable material and to obtain a substantially homogeneous plasticized mass.

Abstract: Pharmaceutical compositions comprising one or more digestive enzymes and one or more gastrointestinal modulators of acid are provided. The one or more digestive enzymes may be coated, e.g., with a lipid. Also disclosed are methods for their use and controlled delivery in treating individuals with neurological, behavioral, infectious, or genetic diseases or conditions susceptible to treatment with digestive enzymes.

Abstract: The present invention relates to an antibacterial agent and a hydrolysate made of at least one extract that has been produced by extraction using ethanol/water from dried plant material of: a) at least one of the plants selected from the group consisting of: Verbena officinalis L., Sambucus nigra L., Primula veris L., Primula elatior (L.) Hill, and Gentiana lutea L.; and a mixture thereof; or b) a mixture of: Verbena officinalis L., Sambucus nigra L., Primula veris L., Gentiana lutea L., and Rumicis herba; and subsequent removal of the ethanol/water extraction agent, wherein the hydrolysate can be obtained from the extract via hydrolytic treatment using a mineral acid. The hydrolyzates according to the invention show a pronounced antibacterial effect against germs relevant to the skin, ears, nose, and throat and respiratory systems.

Abstract: The present invention features a method of making a coated tablet by dipping a core comprising an active agent into a coating liquid and drying said dipped core to form a outer-coating on the core, wherein the coating liquid contains at least one a starch having an amylose content of at least about 50 percent by weight of said starch.

Abstract: Provided is an oral solid preparation of a compound anti-tubercular drug, wherein the active ingredients are rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride. The compound oral solid preparation is a coated tablet with coated core or a coated three-layer tablet, wherein the two active ingredients rifampicin and isoniazid do not contact directly. The compound oral solid preparation not only improves the stability of the compound preparation, but also improves the bioavailability of rifampicin.

Abstract: A process for reducing the intensity of the intrinsic bitter taste of a water soluble active which comprises dry mixing of said active with ?-cyclodextrin.

Abstract: The invention provides novel hydroxystilbene-containing dosage forms, processes for producing these dosage forms and the use thereof for the treatment of menopausal symptoms in women, juvenile oligomenorrhea and dysmenorrhea, primary and secondary amenorrhea or endometritis.

Abstract: Controlled release oral solid dosage form for the reduction of serum cholesterol levels in humans include a drug comprising an alkyl ester of hydroxy substituted naphthalenes (e.g., lovastatin) and a controlled release carrier, such that the dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at about 10 to about 32 hours after oral administration on a once-a-day basis to human patients. The dosage form provides a therapeutically effective reduction in serum cholesterol levels. Methods of reducing serum cholesterol levels in humans are also disclosed.

Abstract: The present application relates to compositions for use in a method of treating and/or preventing mental and behavioral disorders and/or improving mental health and cognitive functions in a subject, comprising: a) Docosahexaenoic acid (DHA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; b) Eicosapentaenoic acid (EPA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; c) ?-linolenic acid (GLA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; and at least a psychostimulant compound selected among methylphenidate HCl, atomoxetine, amphetamine, gamma-hydroxybutyrate, dextroamphetamine, sibutramine, methylenedioxymethamphetamine, and/or an anxiolytic compound selected among fluoxatine, sertraline, paroxetine, fluoroxamine, citralopram, venlafaxine, bupropion, nefazodone, and mirtazapine.